Market Place
Sourcing Support
Soligenix Details Recent Progress And Upcoming Milestones
12 Feb 2026 //
PR NEWSWIRE
Soligenix Reveals 3Q 2025 Financial Results & Achievements
07 Nov 2025 //
PR NEWSWIRE
Soligenix Refreshes US Medical Advisory Board For Lymphoma
14 Oct 2025 //
PR NEWSWIRE
Soligenix Announces Closing Of $7.5 Million Public Offering
30 Sep 2025 //
PR NEWSWIRE
Soligenix Announces Pricing Of $7.5 Million Public Offering
26 Sep 2025 //
PR NEWSWIRE
Soligenix to Present at H.C. Wainwright Global Conference
02 Sep 2025 //
PR NEWSWIRE
Soligenix Reports Q2 2025 Financial Results and Recent
14 Aug 2025 //
PR NEWSWIRE
Soligenix Platform Targets Growing CTCL Therapy Demand
07 Aug 2025 //
GLOBENEWSWIRE
Soligenix Platform Provides Novel Treatment for Underserved CTCL
05 Aug 2025 //
GLOBENEWSWIRE
Soligenix Corporate Update: Key Highlights and Future Milestones
09 Jul 2025 //
PR NEWSWIRE
Soligenix Highlights Dr. Ellen Kim`s Q&A and HyBryte™ in Clinical
06 Jun 2025 //
GLOBENEWSWIRE
Soligenix Announces Q1 2025 Financial Results
09 May 2025 //
PR NEWSWIRE
HyBryte™ Clinical Results Show Continued Post-Treatment Improvement
02 Dec 2024 //
PR NEWSWIRE
Soligenix Announces Recent Accomplishments & Q3 Financial Results
08 Nov 2024 //
PR NEWSWIRE
Soligenix Receives Hong Kong Patent For Synthetic Hypericin
22 Oct 2024 //
PR NEWSWIRE
Soligenix Receives European Patent for Synthetic Hypericin Production
03 Sep 2024 //
PR NEWSWIRE
Soligenix Announces Positive Clinical Results for HyBryte™ in CTCL Treatment
25 Jun 2024 //
PR NEWSWIRE
Soligenix Announces Reverse Stock Split
31 May 2024 //
PR NEWSWIRE
Soligenix Q1 2024 Financials, Accomplishments
10 May 2024 //
PR NEWSWIRE
Soligenix to Present at Upcoming Conferences
06 May 2024 //
PR NEWSWIRE
Soligenix Announces Pricing of $4.75 Million Public Offering
18 Apr 2024 //
PR NEWSWIRE
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results
15 Mar 2024 //
PR NEWSWIRE
Soligenix Announces Formation of Behçet`s Disease Medical Advisory Board
08 Feb 2024 //
PR NEWSWIRE
Soligenix to Present at The Microcap Conference
25 Jan 2024 //
PR NEWSWIRE
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302
04 Jan 2024 //
PR NEWSWIRE
Soligenix, Inc. Announces Adjournment of Annual Meeting
20 Oct 2023 //
PR NEWSWIRE
Soligenix Announces Accomplishments And Second Quarter 2023 Financial Results
21 Aug 2023 //
PR NEWSWIRE
Soligenix Announces Expansion of SGX302 Ph2a in Mild-to-Moderate Psoriasis
11 Jul 2023 //
PR NEWSWIRE
Soligenix Announces Recent Accomplishments And 1Q 2023 FYR Results
15 May 2023 //
PR NEWSWIRE
Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review
11 May 2023 //
PR NEWSWIRE
Soligenix Announces Closing of $8.5 Million Public Offering
09 May 2023 //
PR NEWSWIRE
Soligenix Announces Appointment of Timothy R. Coté, M.D. to its BOD
03 May 2023 //
BUSINESSWIRE
Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics
01 May 2023 //
PR NEWSWIRE
Soligenix Submits Type A Meeting Request to Review Study Evaluating HyBryte
24 Apr 2023 //
PR NEWSWIRE
Soligenix shares take another dip as FDA requests 2nd trial
15 Apr 2023 //
FIERCE BIOTECH
Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA for HyBryte
03 Apr 2023 //
PR NEWSWIRE
Soligenix Announces Recent Accomplishments And Year-End 2022 Financial Results
31 Mar 2023 //
PR NEWSWIRE
Soligenix Submits Type A Meeting Request to U.S. FDA for HyBryte NDA
09 Mar 2023 //
PR NEWSWIRE
Soligenix stock sinks as FDA refuses lymphoma application
15 Feb 2023 //
FIERCE BIOTECH
Soligenix Announces Reverse Stock Split
09 Feb 2023 //
PR NEWSWIRE
Soligenix Invited to Present at the Virtual Investor Summit Event
19 Jan 2023 //
PR NEWSWIRE
Soligenix Announces Distribution of Series D Preferred Stock
23 Dec 2022 //
PR NEWSWIRE
Soligenix opens patient enrolment for Phase IIa trial of psoriasis therapy
19 Dec 2022 //
CLINICALTRIALSARENA
Soligenix opens patient enrolment for Phase IIa trial of psoriasis therapy
19 Dec 2022 //
CLINICALTRIALSARENA
Soligenix Announces Submission of New Drug Application to the FDA for HyBryte
15 Dec 2022 //
PRNEWSWIRE
Soligenix to Receive $1.2 M in Non-Dilutive Funding
15 Nov 2022 //
PRNEWSWIRE
Soligenix Announces Adjournment of Annual Meeting
20 Oct 2022 //
PRNEWSWIRE
Soligenix Announces Partial Adjournment of Annual Meeting
23 Sep 2022 //
PRNEWSWIRE
US FDA awards $2.6 million orphan products development grant to Soligenix
08 Sep 2022 //
PHARMABIZ
USFDA Awards $2.6 Million Orphan Products Development Grant for Study of HyBryte
06 Sep 2022 //
PRNEWSWIRE
Soligenix Announces Recent Accomplishments And 2022 Financial Results
12 Aug 2022 //
PRNEWSWIRE
Soligenix Receives Agreement on Initial Pediatric Study Plan for HyBryte
27 Jul 2022 //
PRNEWSWIRE
Soligenix Announces Strategic Partnership with SERB Pharmaceuticals
25 Jul 2022 //
PRNEWSWIRE
HyBryte PIII FLASH Study for Cutaneous T-Cell Lymphoma Published
20 Jul 2022 //
PRNEWSWIRE
Soligenix gets FDA clearance for Phase II psoriasis trial
30 Jun 2022 //
CLINICALTRIALSARENA
FDA Clears Soligenix`s IND for PII Trial of Synthetic Hypericin in Psoriasis
28 Jun 2022 //
PRNEWSWIRE
Soligenix: Protection using Bivalent Thermostabilized Filovirus Vaccine
23 Jun 2022 //
PRNEWSWIRE
Soligenix Receives US Patent Allowance for its Thermostabilized Vaccine Platform
23 May 2022 //
PRNEWSWIRE
Soligenix to Present at the H.C. Wainwright Global Investment Conference
18 May 2022 //
PRNEWSWIRE
Soligenix Announces First Quarter 2022 Financial Results
13 May 2022 //
PRNEWSWIRE
